SCHEMBL2185175

SCHEMBL2185175

C=CCS(=O)(=O)N1CCCCCC1

nearest known ligand 0.42

Predicted protein targets (top 14)

geneUniProtsupporting neighboursconfidence
CA1 P00915 2/20 0.42
CA2 P00918 2/20 0.42
POLB P06746 1/20 0.42
TSHR P16473 4/20 0.41
HPGD P15428 1/20 0.41
KMT2A Q03164 4/20 0.41
ALDH1A1 P00352 3/20 0.37
KDM4E B2RXH2 2/20 0.37
MAPT P10636 1/20 0.37
USP2 O75604 1/20 0.35
MEN1 O00255 3/20 0.34
CYP3A4 P08684 1/20 0.33
CYP2C9 P11712 1/20 0.33
CYP2C19 P33261 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2185192 0.98 CA1 (0.39) CA1CA2POLBTSHRHPGD
SCHEMBL5257406 0.93 KMT2A (0.37) CA1CA2POLBTSHRHPGD
1,2-Dichlorobenzene SCHEMBL27756619 0.83 ALDH1A1 (0.59) POLBTSHRHPGDKMT2AALDH1A1
Cyclopropane SCHEMBL27924381 0.82 KDM4E (0.47) CA2KMT2AALDH1A1KDM4EMAPT
Fluorobenzene SCHEMBL27883519 0.82 TSHR (0.51) TSHRHPGDKMT2AALDH1A1KDM4E
SCHEMBL83829 0.78 MEN1 (0.32) KMT2AMEN1
SCHEMBL12821513 0.78 KDM4E (0.42) KMT2AALDH1A1KDM4EMAPTUSP2
SCHEMBL2186346 0.78 CA12 (0.48) POLBTSHRALDH1A1KDM4EMAPT
SCHEMBL2187580 0.78 KDM4E (0.42) KMT2AALDH1A1KDM4EMAPTUSP2
SCHEMBL2186390 0.77 ALDH1A1 (0.36) KMT2AALDH1A1MEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2346507-A1 USE OF QUINAZOLINE DERIVATIVES FOR THE TREATMENT OF VIRAL DISEASES Boehringer Ingelheim International GmbH (DE) 2011-07-27 EP claimed
WO-2010026029-A1 USE OF QUINAZOLINE DERIVATIVES FOR THE TREATMENT OF VIRAL DISEASES BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2010-03-11 WO claimed
EP-1478363-B1 FUSED AZABICYCLIC COMPOUNDS THAT INHIBIT VANILLOID RECEPTOR SUBTYPE 1 (VR1) RECEPTOR ABBOTT LAB (US) 2009-01-14 EP disclosed